Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 7/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | PRKX | P51817 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.34 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.34 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328559 | 0.79 | KMO (0.41) | KMOPIM1CDC7DAPK3MAP4K4 | |
| SCHEMBL15051745 | 0.78 | GRM5 (0.40) | CYP1A1CYP1B1KMOPIM1CDC7 | |
| SCHEMBL19355319 | 0.76 | ASIC3 (0.55) | CYP1A1CYP1B1KMOAAK1 | |
| SCHEMBL15339601 | 0.76 | KDM4E (0.46) | KMOPIM1CDC7DAPK3MAP4K4 | |
| SCHEMBL15356377 | 0.76 | AAK1 (0.34) | KMOPIM1CDC7DAPK3MAP4K4 | |
| SCHEMBL16635390 | 0.76 | AAK1 (0.39) | KMOPIM1CDC7DAPK3MAP4K4 | |
| SCHEMBL22838564 | 0.73 | CYP1A2 (0.51) | CLK4ALDH1A1 | |
| SCHEMBL15077464 | 0.73 | KMO (0.45) | CYP1A1CYP1B1KMOPIM1CDC7 | |
| SCHEMBL3921315 | 0.72 | MKNK1 (0.45) | KMO | |
| SCHEMBL21010622 | 0.72 | AAK1 (0.37) | CYP1A1CYP1B1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574179-B | DNA-PK inhibitors | 山东轩竹医药科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-106977495-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20200109130-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-04-09 | — | — | US | disclosed |
| US-20200062732-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-02-27 | — | — | US | disclosed |
| WO-2015058031-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | WO | disclosed |
| EP-2841428-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| WO-2013163190-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013163190-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045869-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | CYP1A1 2554/4885CYP1B1 2274/4885KMO 2181/4885 |
| US-20200109130-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | CYP1A1 2554/4885CYP1B1 2274/4885KMO 2181/4885 |
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | CYP1A1 2554/4885CYP1B1 2274/4885KMO 2181/4885 |
| US-20200062732-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | CYP1A1 2554/4885CYP1B1 2274/4885KMO 2181/4885 |
| US-20130281431-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | CYP1A1 2554/4885CYP1B1 2274/4885KMO 2181/4885 |
| US-11021465-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | CYP1A1 2554/4885CYP1B1 2274/4885KMO 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.